Reduced Intensity AlloTransplant For Osteopetrosis

Phase 2

Terminated

Interventions: Procedure: Stem Cell or Umbilical Cord Blood Transplantation
Drug: Campath, Busulfan, Clofarabine
Procedure: Total Lymphoid Irradiation

Brief Summary: We believe that hematopoietic stem cell transplantation (HSCT) will help subjects with Osteopetrosis generate functioning osteoclasts, and by so doing assist in the resolution of the abnormal bone architecture, and the anemia and bone marrow failure that is also characteristic of this disease. However, we have found in past studies that approximately 30% of Osteopetrosis patients do not engraft. Therefore, in this study, we plan to use a different combination of pre-transplant drugs to try to make transplants safer for this disease, as well as to provide a second infusion of stem cells in patients with matched related or unrelated donors. The purpose of this research is to find a safer and more effective means of performing stem cell transplantation in patients with Osteopetrosis, using chemotherapy and radiation designed to bring about engraftment and lessen transplant mortality.

Detailed Description: This transplant protocol will test the following: 1) the ability to achieve engraftment with the reduced intensity protocol, 2) the mortality associated with transplant by day 100, 3) patient outcomes, based on differential imaging and biologic evaluations prior to transplantation and at designated points after transplantation (day 100, 6 months, 1, 2 and 5 years). Additional biologic studies will include microarray analysis, Campath levels just prior to the administration of the graft, and establishment of mesenchymal stem cell lines. In older patients, studies to evaluation osteoclast differentiation and function will also be offered.

Recruitment & Eligibility

Inclusion Criteria

Patients eligible for transplantation under this protocol will be <45 years of age, and will be diagnosed with severe osteopetrosis. This will be defined as having the following manifestations of the disease.
Bones that are uniformly markedly dense based on skeletal survey
No history that would suggest autosomal dominant inheritance
Evidence of hematologic changes that are attributed to the underlying disease, including the need for ongoing transfusions, OR
the presence of progressive anemia or thrombocytopenia, OR a white blood cell differential with a predominance of immature forms and evidence of extramedullary hematopoiesis, OR
persistence of serious infectious complications that are thought to be due to the abnormal architecture of the bone that are resistant to surgical and medical interventions.

Exclusion Criteria

Patients >45 years of age
Evidence of hepatic failure
pulmonary dysfunction sufficient to substantially increase the risk of transplant
Renal dysfunction with glomerular filtration rate (GFR) <30% of predicted.
Cardiac compromise sufficient to substantially increase the risk of transplantation
Severe, stable neurologic impairment.
Human immunodeficiency virus (HIV) positivity.
Pregnant or lactating females

Arm && Interventions

Group	Intervention	Description
Intent-To-Treat	Stem Cell or Umbilical Cord Blood Transplantation	Patients enrolled and received study treatment.
Intent-To-Treat	Campath, Busulfan, Clofarabine	Patients enrolled and received study treatment.
Intent-To-Treat	Total Lymphoid Irradiation	Patients enrolled and received study treatment.

Primary Outcome Measures

Name	Time	Method
Number of Patients Achieving Donor Cell Engraftment	Day 100	Number of patients with persistent presence of donor-derived cells at Day 100

Secondary Outcome Measures

Name	Time	Method
Number of Patients With Transplant Related Death	Day 100	Number of participants died during study by Day 100 and reason for death was related to transplant.
Number of Patients With Transplant Related Toxicity	Day 100	Number of patients experiencing adverse effects due to transplant categorized by body system using Common Terminology Criteria for Adverse Events coding from the National Cancer Institute, Version 3.0.
Differential Imaging and Biologic Evaluations	Day 100, 6 months, 1, 2 and 5 years	These outcome measures were not assessed due to early study termination.